About ArQule (NASDAQ:ARQL)
ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. It offers Derazantinib (ARQ 087), a multi-kinase inhibitor of the fibroblast growth factor receptor (FGFR) family that is in a registration trial in intrahepatic cholangiocarcinoma with FGFR2 fusions. The company's clinical-stage products include Miransertib (ARQ 092), an inhibitor of the AKT serine/threonine kinase in Phase 1/2 clinical trial in rare Overgrowth Diseases, Phase 1 clinical trial in the rare disease, and in Phase 1b in oncology in combination with the hormonal therapy and anastrozole; ARQ 751, a next-generation inhibitor of AKT that is in Phase I clinical trial for solid tumors harboring the AKT1 or PI3K mutation; ARQ 761, a ß-lapachone analog evaluated as a promoter of NQO1-mediated programmed cancer cell death which is in Phase 1/2 clinical trial in multiple oncology; and ARQ 531, an orally bioavailable, potent and reversible inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase 1 for B-cell malignancies refractory to other therapeutic options. It has collaboration agreement with Roivant Sciences Ltd. to develop derazantinib, a pan-FGFR inhibitor. ArQule, Inc. was founded in 1993 and is headquartered in Burlington, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-12.79
Forward P/E Ratio-20.79
Sales & Book Value
Annual Sales$4.71 million
Price / Sales101.18
Price / CashN/A
Book Value$0.16 per share
Price / Book31.19
EPS (Most Recent Fiscal Year)($0.39)
Return on Equity-281.59%
Return on Assets-73.14%
ArQule (NASDAQ:ARQL) Frequently Asked Questions
What is ArQule's stock symbol?
ArQule trades on the NASDAQ under the ticker symbol "ARQL."
How were ArQule's earnings last quarter?
ArQule, Inc. (NASDAQ:ARQL) issued its quarterly earnings data on Monday, May, 7th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.01. The biotechnology company earned $4.14 million during the quarter, compared to the consensus estimate of $2.27 million. During the same period last year, the business earned ($0.11) EPS. View ArQule's Earnings History.
When is ArQule's next earnings date?
What price target have analysts set for ARQL?
5 analysts have issued 12 month price targets for ArQule's shares. Their forecasts range from $4.00 to $7.00. On average, they expect ArQule's share price to reach $5.75 in the next twelve months. View Analyst Ratings for ArQule.
Who are some of ArQule's key competitors?
Some companies that are related to ArQule include Phibro Animal Health (PAHC), Aimmune Therapeutics (AIMT), AnaptysBio (ANAB), PTC Therapeutics (PTCT), Myokardia (MYOK), Mallinckrodt (MNK), Biohaven Pharmaceutical (BHVN), Zogenix (ZGNX), TherapeuticsMD (TXMD), Cambrex (CBM), Pacira Pharmaceuticals (PCRX), G1 Therapeutics (GTHX), ARMO Biosciences (ARMO), Innoviva (INVA) and Wave Life Sciences (WVE).
Who are ArQule's key executives?
ArQule's management team includes the folowing people:
- Mr. Paolo Pucci, CEO & Director (Age 57)
- Mr. Peter S. Lawrence J.D., Pres, COO & Sec. (Age 55)
- Mr. Robert J. Weiskopf, CFO & Treasurer (Age 67)
- Dr. Brian Schwartz, Chief Medical Officer (Age 56)
- Dawn Schottlandt CFA, Sr. Director of Investor Relations & Corp. Communications
Has ArQule been receiving favorable news coverage?
News stories about ARQL stock have been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. ArQule earned a news sentiment score of 0.16 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 47.44 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are ArQule's major shareholders?
ArQule's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include First Eagle Investment Management LLC (17.03%), BIOTECHNOLOGY VALUE FUND L P (12.30%), Sphera Funds Management LTD. (2.60%), Millennium Management LLC (1.98%), DAFNA Capital Management LLC (0.56%) and JPMorgan Chase & Co. (0.28%). Company insiders that own ArQule stock include Paolo Pucci, Patrick J Zenner, Ran Nussbaum, Ronald M Lindsay and Value Fund L P Biotechnology. View Institutional Ownership Trends for ArQule.
Which institutional investors are selling ArQule stock?
Which institutional investors are buying ArQule stock?
ARQL stock was purchased by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Millennium Management LLC, Candriam Luxembourg S.C.A., Tibra Equities Europe Ltd, Arnhold LLC, JPMorgan Chase & Co., Element Capital Management LLC and Jane Street Group LLC. Company insiders that have bought ArQule stock in the last two years include Paolo Pucci, Patrick J Zenner, Ran Nussbaum and Ronald M Lindsay. View Insider Buying and Selling for ArQule.
How do I buy shares of ArQule?
Shares of ARQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ArQule's stock price today?
One share of ARQL stock can currently be purchased for approximately $4.99.
How big of a company is ArQule?
ArQule has a market capitalization of $476.52 million and generates $4.71 million in revenue each year. The biotechnology company earns $-29,200,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. ArQule employs 32 workers across the globe.
How can I contact ArQule?
ArQule's mailing address is ONE WALL STREET, BURLINGTON MA, 01803. The biotechnology company can be reached via phone at 781-994-0300 or via email at [email protected]
MarketBeat Community Rating for ArQule (ARQL)MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote "Outperform" if you believe ARQL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARQL will underperform the S&P 500 over the long term. You may vote once every thirty days.